China Resources Shuanghe announced that China Resources Shuanghe Xiang Chinese Pharmaceutical Co., Ltd., a holding subsidiary of the company, previously submitted an application for marketing approval of oxacipin tablets in 0.15g format. It was approved for marketing by the State Drug Administration and obtained a “Drug Registration Certificate” on August 25, 2026. This certification is considered to have passed the consistency evaluation.

China Resources Shuanghe announced that China Resources Shuanghe Xiang Chinese Pharmaceutical Co., Ltd., a holding subsidiary of the company, previously submitted an application for marketing approval of oxacipin tablets in 0.15g format. It was approved for marketing by the State Drug Administration and obtained a “Drug Registration Certificate” on August 25, 2026. This certification is considered to have passed the consistency evaluation.